Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regulus (RGLS – Research Report), Axsome Therapeutics (AXSM – Research Report) and Olink Holding (OLK – Research Report).
Regulus (RGLS)
In a report issued on March 22, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Regulus, with a price target of $6.00. The company’s shares closed last Tuesday at $2.85.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regulus with a $7.25 average price target, implying a 155.3% upside from current levels. In a report issued on March 22, Canaccord Genuity also maintained a Buy rating on the stock with a $11.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Axsome Therapeutics (AXSM)
In a report issued on March 25, Joel Beatty from Robert W. Baird maintained a Buy rating on Axsome Therapeutics, with a price target of $108.00. The company’s shares closed last Tuesday at $76.72.
According to TipRanks.com, Beatty is a 5-star analyst with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $125.33, which is a 59.9% upside from current levels. In a report issued on March 15, Mizuho Securities also maintained a Buy rating on the stock with a $108.00 price target.
Olink Holding (OLK)
Leerink Partners analyst Puneet Souda reiterated a Hold rating on Olink Holding on March 25 and set a price target of $26.00. The company’s shares closed last Tuesday at $24.06, close to its 52-week high of $26.01.
According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Olink Holding is a Hold with an average price target of $26.00, which is a 6.6% upside from current levels. In a report issued on March 25, Canaccord Genuity also maintained a Hold rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RGLS:
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
- Regulus reports Q4 EPS (40c), consensus (39c)
- Regulus options imply 25.8% move in share price post-earnings
- Regulus price target lowered to $11 from $12 at Canaccord
- Leerink bullish on Regulus, initiates with an Outperform
